Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Chimeric Antigen Receptor Cell Therapy market report explains the definition, types, applications, major countries, and major players of the Chimeric Antigen Receptor Cell Therapy market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Hebei Senlang Biotechnology Inc Ltd
Beijing Immunochina Medical Science & Technology Co Ltd
Celgene Corp
Bellicum Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Amgen Inc
Cell Medica Ltd
HRAIN Biotechnology Co Ltd
Celularity Inc
Celyad SA
Fosun Pharmaceutical AG
Nanjing Legend Biotech Co Ltd
CARsgen Therapeutics Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Nkarta Inc
NantKwest Inc
Gilead Sciences Inc
Autolus Therapeutics Plc
Takara Bio Inc
Hangzhou Converd Co Ltd
Bristol-Myers Squibb Co
Sorrento Therapeutics Inc
Novartis AG
Guangzhou Anjie Biomedical Technology Co Ltd
Cellular Biomedicine Group Inc
Ono Pharmaceutical Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
bluebird bio Inc
By Type:
Monotherapy
Combination Therapy
By End-User:
Acute Leukemia
Non-hodgkin's Lymphoma
Multiple Myeloma
Transplant Rejection
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Chimeric Antigen Receptor Cell Therapy Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Chimeric Antigen Receptor Cell Therapy Outlook to 2028- Original Forecasts
-
2.2 Chimeric Antigen Receptor Cell Therapy Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Chimeric Antigen Receptor Cell Therapy Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Chimeric Antigen Receptor Cell Therapy Market- Recent Developments
-
6.1 Chimeric Antigen Receptor Cell Therapy Market News and Developments
-
6.2 Chimeric Antigen Receptor Cell Therapy Market Deals Landscape
7 Chimeric Antigen Receptor Cell Therapy Raw Materials and Cost Structure Analysis
-
7.1 Chimeric Antigen Receptor Cell Therapy Key Raw Materials
-
7.2 Chimeric Antigen Receptor Cell Therapy Price Trend of Key Raw Materials
-
7.3 Chimeric Antigen Receptor Cell Therapy Key Suppliers of Raw Materials
-
7.4 Chimeric Antigen Receptor Cell Therapy Market Concentration Rate of Raw Materials
-
7.5 Chimeric Antigen Receptor Cell Therapy Cost Structure Analysis
-
7.5.1 Chimeric Antigen Receptor Cell Therapy Raw Materials Analysis
-
7.5.2 Chimeric Antigen Receptor Cell Therapy Labor Cost Analysis
-
7.5.3 Chimeric Antigen Receptor Cell Therapy Manufacturing Expenses Analysis
8 Global Chimeric Antigen Receptor Cell Therapy Import and Export Analysis (Top 10 Countries)
-
8.1 Global Chimeric Antigen Receptor Cell Therapy Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Chimeric Antigen Receptor Cell Therapy Export by Region (Top 10 Countries) (2017-2028)
9 Global Chimeric Antigen Receptor Cell Therapy Market Outlook by Types and Applications to 2022
-
9.1 Global Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Monotherapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Combination Therapy Consumption and Growth Rate (2017-2022)
-
9.2 Global Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Acute Leukemia Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Non-hodgkin's Lymphoma Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Transplant Rejection Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Chimeric Antigen Receptor Cell Therapy Market Analysis and Outlook till 2022
-
10.1 Global Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.2.2 Canada Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.2.3 Mexico Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.2 UK Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.3 Spain Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.4 Belgium Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.5 France Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.6 Italy Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.7 Denmark Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.8 Finland Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.9 Norway Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.10 Sweden Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.11 Poland Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.12 Russia Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.3.13 Turkey Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.2 Japan Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.3 India Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.4 South Korea Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.5 Pakistan Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.6 Bangladesh Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.7 Indonesia Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.8 Thailand Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.9 Singapore Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.10 Malaysia Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.11 Philippines Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.4.12 Vietnam Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.2 Colombia Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.3 Chile Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.4 Argentina Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.5 Venezuela Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.6 Peru Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.7 Puerto Rico Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.5.8 Ecuador Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.6.2 Kuwait Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.6.3 Oman Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.6.4 Qatar Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.6.5 Saudi Arabia Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.6.6 United Arab Emirates Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.7.2 South Africa Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.7.3 Egypt Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.7.4 Algeria Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
-
10.8.2 New Zealand Chimeric Antigen Receptor Cell Therapy Consumption (2017-2022)
11 Global Chimeric Antigen Receptor Cell Therapy Competitive Analysis
-
11.1 Hebei Senlang Biotechnology Inc Ltd
-
11.1.1 Hebei Senlang Biotechnology Inc Ltd Company Details
-
11.1.2 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.1.4 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Beijing Immunochina Medical Science & Technology Co Ltd
-
11.2.1 Beijing Immunochina Medical Science & Technology Co Ltd Company Details
-
11.2.2 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.2.4 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Celgene Corp
-
11.3.1 Celgene Corp Company Details
-
11.3.2 Celgene Corp Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Celgene Corp Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.3.4 Celgene Corp Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Bellicum Pharmaceuticals Inc
-
11.4.1 Bellicum Pharmaceuticals Inc Company Details
-
11.4.2 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.4.4 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Daiichi Sankyo Co Ltd
-
11.5.1 Daiichi Sankyo Co Ltd Company Details
-
11.5.2 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.5.4 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Amgen Inc
-
11.6.1 Amgen Inc Company Details
-
11.6.2 Amgen Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Amgen Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.6.4 Amgen Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Cell Medica Ltd
-
11.7.1 Cell Medica Ltd Company Details
-
11.7.2 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.7.4 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 HRAIN Biotechnology Co Ltd
-
11.8.1 HRAIN Biotechnology Co Ltd Company Details
-
11.8.2 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.8.4 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Celularity Inc
-
11.9.1 Celularity Inc Company Details
-
11.9.2 Celularity Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Celularity Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.9.4 Celularity Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Celyad SA
-
11.10.1 Celyad SA Company Details
-
11.10.2 Celyad SA Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Celyad SA Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.10.4 Celyad SA Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Fosun Pharmaceutical AG
-
11.11.1 Fosun Pharmaceutical AG Company Details
-
11.11.2 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.11.4 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Nanjing Legend Biotech Co Ltd
-
11.12.1 Nanjing Legend Biotech Co Ltd Company Details
-
11.12.2 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.12.4 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 CARsgen Therapeutics Ltd
-
11.13.1 CARsgen Therapeutics Ltd Company Details
-
11.13.2 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.13.4 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
-
11.14.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Company Details
-
11.14.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.14.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Nkarta Inc
-
11.15.1 Nkarta Inc Company Details
-
11.15.2 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.15.4 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 NantKwest Inc
-
11.16.1 NantKwest Inc Company Details
-
11.16.2 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.16.4 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Gilead Sciences Inc
-
11.17.1 Gilead Sciences Inc Company Details
-
11.17.2 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.17.4 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 Autolus Therapeutics Plc
-
11.18.1 Autolus Therapeutics Plc Company Details
-
11.18.2 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.18.4 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Takara Bio Inc
-
11.19.1 Takara Bio Inc Company Details
-
11.19.2 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.19.4 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Hangzhou Converd Co Ltd
-
11.20.1 Hangzhou Converd Co Ltd Company Details
-
11.20.2 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.20.4 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.20.5 Recent Research and Development Strategies
-
11.21 Bristol-Myers Squibb Co
-
11.21.1 Bristol-Myers Squibb Co Company Details
-
11.21.2 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.21.3 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.21.4 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.21.5 Recent Research and Development Strategies
-
11.22 Sorrento Therapeutics Inc
-
11.22.1 Sorrento Therapeutics Inc Company Details
-
11.22.2 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.22.3 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.22.4 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.22.5 Recent Research and Development Strategies
-
11.23 Novartis AG
-
11.23.1 Novartis AG Company Details
-
11.23.2 Novartis AG Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.23.3 Novartis AG Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.23.4 Novartis AG Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.23.5 Recent Research and Development Strategies
-
11.24 Guangzhou Anjie Biomedical Technology Co Ltd
-
11.24.1 Guangzhou Anjie Biomedical Technology Co Ltd Company Details
-
11.24.2 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.24.3 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.24.4 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.24.5 Recent Research and Development Strategies
-
11.25 Cellular Biomedicine Group Inc
-
11.25.1 Cellular Biomedicine Group Inc Company Details
-
11.25.2 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.25.3 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.25.4 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.25.5 Recent Research and Development Strategies
-
11.26 Ono Pharmaceutical Co Ltd
-
11.26.1 Ono Pharmaceutical Co Ltd Company Details
-
11.26.2 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.26.3 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.26.4 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.26.5 Recent Research and Development Strategies
-
11.27 Juno Therapeutics Inc
-
11.27.1 Juno Therapeutics Inc Company Details
-
11.27.2 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.27.3 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.27.4 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.27.5 Recent Research and Development Strategies
-
11.28 Kite Pharma Inc
-
11.28.1 Kite Pharma Inc Company Details
-
11.28.2 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.28.3 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.28.4 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.28.5 Recent Research and Development Strategies
-
11.29 bluebird bio Inc
-
11.29.1 bluebird bio Inc Company Details
-
11.29.2 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
11.29.3 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
11.29.4 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
11.29.5 Recent Research and Development Strategies
12 Global Chimeric Antigen Receptor Cell Therapy Market Outlook by Types and Applications to 2028
-
12.1 Global Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Acute Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Non-hodgkin's Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Chimeric Antigen Receptor Cell Therapy Market Analysis and Outlook to 2028
-
13.1 Global Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.2.2 Canada Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.2.3 Mexico Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.2 UK Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.3 Spain Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.4 Belgium Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.5 France Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.6 Italy Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.7 Denmark Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.8 Finland Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.9 Norway Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.10 Sweden Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.11 Poland Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.12 Russia Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.3.13 Turkey Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.2 Japan Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.3 India Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.4 South Korea Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.8 Thailand Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.9 Singapore Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.11 Philippines Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.2 Colombia Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.3 Chile Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.4 Argentina Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.6 Peru Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.6.3 Oman Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.6.4 Qatar Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.7.2 South Africa Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.7.3 Egypt Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.7.4 Algeria Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Chimeric Antigen Receptor Cell Therapy Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Chimeric Antigen Receptor Cell Therapy
-
Figure of Chimeric Antigen Receptor Cell Therapy Picture
-
Table Global Chimeric Antigen Receptor Cell Therapy Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Chimeric Antigen Receptor Cell Therapy Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Monotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Combination Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Acute Leukemia Consumption and Growth Rate (2017-2022)
-
Figure Global Non-hodgkin's Lymphoma Consumption and Growth Rate (2017-2022)
-
Figure Global Multiple Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global Transplant Rejection Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Table North America Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure United States Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Canada Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Mexico Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table Europe Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure Germany Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure UK Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Spain Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Belgium Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure France Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Italy Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Denmark Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Finland Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Norway Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Sweden Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Poland Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Russia Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Turkey Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table APAC Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure China Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Japan Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure India Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure South Korea Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Thailand Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Singapore Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Philippines Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table South America Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure Brazil Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Colombia Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Chile Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Argentina Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Peru Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table GCC Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure Bahrain Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Oman Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Qatar Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table Africa Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure Nigeria Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure South Africa Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Egypt Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure Algeria Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table Oceania Chimeric Antigen Receptor Cell Therapy Consumption by Country (2017-2022)
-
Figure Australia Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Chimeric Antigen Receptor Cell Therapy Consumption and Growth Rate (2017-2022)
-
Table Hebei Senlang Biotechnology Inc Ltd Company Details
-
Table Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Beijing Immunochina Medical Science & Technology Co Ltd Company Details
-
Table Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Celgene Corp Company Details
-
Table Celgene Corp Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Corp Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Celgene Corp Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Bellicum Pharmaceuticals Inc Company Details
-
Table Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Daiichi Sankyo Co Ltd Company Details
-
Table Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Amgen Inc Company Details
-
Table Amgen Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Amgen Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Cell Medica Ltd Company Details
-
Table Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table HRAIN Biotechnology Co Ltd Company Details
-
Table HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Celularity Inc Company Details
-
Table Celularity Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celularity Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Celularity Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Celyad SA Company Details
-
Table Celyad SA Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celyad SA Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Celyad SA Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Fosun Pharmaceutical AG Company Details
-
Table Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Nanjing Legend Biotech Co Ltd Company Details
-
Table Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table CARsgen Therapeutics Ltd Company Details
-
Table CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Company Details
-
Table Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Nkarta Inc Company Details
-
Table Nkarta Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Nkarta Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Nkarta Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table NantKwest Inc Company Details
-
Table NantKwest Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table NantKwest Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table NantKwest Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Gilead Sciences Inc Company Details
-
Table Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Autolus Therapeutics Plc Company Details
-
Table Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Takara Bio Inc Company Details
-
Table Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Hangzhou Converd Co Ltd Company Details
-
Table Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Bristol-Myers Squibb Co Company Details
-
Table Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Sorrento Therapeutics Inc Company Details
-
Table Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Novartis AG Company Details
-
Table Novartis AG Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Novartis AG Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Guangzhou Anjie Biomedical Technology Co Ltd Company Details
-
Table Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Cellular Biomedicine Group Inc Company Details
-
Table Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Ono Pharmaceutical Co Ltd Company Details
-
Table Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Juno Therapeutics Inc Company Details
-
Table Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table Kite Pharma Inc Company Details
-
Table Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Table bluebird bio Inc Company Details
-
Table bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Sales, Price, Value and Gross Profit (2017-2022)
-
Table bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Main Business and Markets Served
-
Table bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Product Portfolio
-
Figure Global Monotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Combination Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Acute Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-hodgkin's Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Multiple Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Table North America Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure United States Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure Germany Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure China Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure Brazil Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Chimeric Antigen Receptor Cell Therapy Consumption Forecast by Country (2022-2028)
-
Figure Australia Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Chimeric Antigen Receptor Cell Therapy Consumption Forecast and Growth Rate (2022-2028)
-
